Clinical trial
High Dose Gefitinib for the Treatment of Carcinomatous Meningitis in Adult…
NCT00372515 · David M. Jackman, MD, Other · Completed
Key facts
| NCT number | NCT00372515 |
|---|---|
| Title | High Dose Gefitinib for the Treatment of Carcinomatous Meningitis in Adult Patients With Non-Small Cell Lung Cancer and Known or Suspected EGFR Mutations |
| Official title | Phase I Study of High Dose Gefitinib (Iressa) for the Treatment of Carcinomatous Meningitis in Adult Patients With Non-Small Cell Lung Cancer and Known or Suspected EGFR Mutations |
| Lead sponsor | David M. Jackman, MD, Other |
| Collaborators | AstraZeneca Industry Massachusetts General Hospital |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Non-Small Cell Lung Cancer |
| Intervention type | Drug |
| Interventions | Gefitinib |
| Enrollment | 7 |
| Start date | Jun 1, 2006 |
| Primary completion | Dec 1, 2012 |
| Completion | Apr 1, 2015 |
| First posted | Sep 7, 2006 |
| Last update posted | Jan 31, 2018 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: